Higher doses of the investigational therapy efzofitimod significantly reduced relapse rates after a dose of a corticosteroid was reduced…
Articles by Steve Bryson, PhD
Most cardiac sarcoidosis patients respond to six months of first-line treatment with the corticosteroid prednisolone and show reduced…
Despite advances in testing, fewer than one of every six people evaluated for suspected neurosarcoidosis — sarcoidosis affecting the…
Patient and physician education, trust-building, and support mechanisms are needed to reduce barriers to clinical trial participation for Black people…
In advance of Sarcoidosis Awareness Month in April, the Foundation for Sarcoidosis Research (FSR) and aTyr Pharma will…
Researchers have uncovered a network of abnormally activated immune cells and fibroblasts — the primary active cell of connective tissue…
Findings of defects in the heart’s right ventricle, as assessed with an MRI scan, can predict the occurrence of cardiovascular…
A Phase 3 clinical trial testing the ability of efzofitimod to safely improve lung function and reduce corticosteroid usage…
Researchers have developed a highly selective and sensitive test to detect neuropilin-2 (NRP2), the therapeutic protein target of efzofitimod,…
The Foundation for Sarcoidosis Research (FSR) has awarded pulmonologist Nancy Lin, MD, at National Jewish Health, the FSR Sarcoidosis…